Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free ELTX Stock Alerts

Elicio Therapeutics (ELTX) Financials

Elicio Therapeutics logo
$3.12 +0.04 (+1.30%)
Closing price 07/22/2026 04:00 PM Eastern
Extended Trading
$3.10 -0.02 (-0.67%)
As of 07/22/2026 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Elicio Therapeutics

Annual Income Statements for Elicio Therapeutics

This table shows Elicio Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -80 -55 -28 -35 -52 -40
Consolidated Net Income / (Loss)		 -80 -55 -28 -35 -52 -40
Net Income / (Loss) Continuing Operations		 -80 -55 -28 -35 -52 -40
Total Pre-Tax Income 		-80 -55 -28 -35 -52 -40
Total Operating Income		 -55 -39 -24 -36 -45 -38
Total Gross Profit		 1.69 28 0.00 0.00 0.00 0.00
Total Revenue		 2.88 28 0.00 0.00 0.00 0.00
Total Cost of Revenue		 1.19 0.43 0.00 0.00 0.00 0.00
Total Operating Expenses		 57 67 24 36 45 38
Selling, General & Admin Expense		 18 18 5.63 12 11 13
Research & Development Expense		 39 49 18 24 34 25
Total Other Income / (Expense), net		 -25 -15 -4.48 0.55 -6.91 -1.86
Interest Expense		 8.85 0.94 3.60 0.45 0.46 1.13
Interest & Investment Income		 -0.07 -0.10 0.07 0.37 0.78 0.78
Other Income / (Expense), net		 -16 -14 -0.95 0.63 -7.24 -1.50
Income Tax Expense		 - - - 0.00 0.00 0.00
Basic Earnings per Share		 ($5.43) ($1.93) ($89.27) ($6.96) ($4.25) ($2.58)
Weighted Average Basic Shares Outstanding		 14.76M 28.24M 316.00K 5.06M 12.20M 15.31M
Diluted Earnings per Share		 ($5.43) ($1.93) ($89.27) ($6.96) ($4.25) ($2.58)
Weighted Average Diluted Shares Outstanding		 14.76M 28.24M 316.00K 5.06M 12.20M 15.31M
Weighted Average Basic & Diluted Shares Outstanding		 - 29.96M 30.11M 10.24M 15.95M 18.40M

Quarterly Income Statements for Elicio Therapeutics

This table shows Elicio Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -11 -8.92 -12 -7.23 -19 -14 -11 -11 -10 -7.72 -12
Consolidated Net Income / (Loss)		 -11 -8.95 -12 -7.23 -19 -14 -11 -11 -10 -7.72 -12
Net Income / (Loss) Continuing Operations		 -11 -9.05 -12 -7.23 -19 -14 -11 -11 -10 -7.72 -12
Total Pre-Tax Income 		-11 -9.05 -12 -7.23 -19 -14 -11 -11 -10 -7.72 -12
Total Operating Income		 -11 -9.39 -10 -11 -10 -13 -11 -10 -8.05 -8.84 -11
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 11 9.39 10 11 10 13 11 10 8.05 8.84 11
Selling, General & Admin Expense		 3.51 3.24 2.68 2.74 3.14 2.77 2.96 3.09 3.01 3.76 3.85
Research & Development Expense		 7.26 6.16 7.56 8.18 7.21 11 7.78 7.01 5.04 5.08 6.76
Total Other Income / (Expense), net		 0.11 0.44 -1.59 3.70 -8.49 -0.53 -0.47 -0.47 -2.04 1.12 -1.22
Interest Expense		 0.00 0.00 0.04 0.05 0.14 0.23 0.18 0.19 0.43 0.34 0.41
Interest & Investment Income		 0.25 0.08 0.15 0.14 0.19 0.31 0.21 0.17 0.20 0.20 0.16
Other Income / (Expense), net		 -0.03 0.26 -1.70 3.61 -8.54 -0.60 -0.51 -0.44 -1.81 1.26 -0.97
Basic Earnings per Share		 ($1.27) $21.69 ($1.15) ($0.64) ($1.39) ($1.07) ($0.87) ($0.66) ($0.60) ($0.45) ($0.65)
Weighted Average Basic Shares Outstanding		 8.38M 5.06M 10.27M 11.28M 13.58M 12.20M 12.95M 16.06M 16.69M 15.31M 18.21M
Diluted Earnings per Share		 ($1.27) $21.69 ($1.15) ($0.64) ($1.39) ($1.07) ($0.87) ($0.66) ($0.60) ($0.45) ($0.65)
Weighted Average Diluted Shares Outstanding		 8.38M 5.06M 10.27M 11.28M 13.58M 12.20M 12.95M 16.06M 16.69M 15.31M 18.21M
Weighted Average Basic & Diluted Shares Outstanding		 8.41M 10.24M 10.27M 10.77M 10.79M 15.95M 16.00M 16.34M 17.49M 18.40M 19.09M

Annual Cash Flow Statements for Elicio Therapeutics

This table details how cash moves in and out of Elicio Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 29 54 -1.63 5.89 5.19 -0.23
Net Cash From Operating Activities		 -23 -53 -22 -33 -37 -37
Net Cash From Continuing Operating Activities		 -23 -53 -22 -33 -37 -37
Net Income / (Loss) Continuing Operations		 -80 -55 -28 -35 -52 -40
Consolidated Net Income / (Loss)		 -80 -55 -28 -35 -52 -40
Depreciation Expense		 0.10 0.09 0.39 0.38 0.32 0.20
Amortization Expense		 8.19 2.59 0.67 0.79 0.93 1.14
Non-Cash Adjustments To Reconcile Net Income		 24 24 5.12 1.39 9.62 4.72
Changes in Operating Assets and Liabilities, net		 25 -25 -0.15 -0.06 3.96 -3.45
Net Cash From Investing Activities		 -0.04 -0.38 -0.65 -0.03 -0.08 -0.02
Net Cash From Continuing Investing Activities		 -0.04 -0.38 -0.65 -0.03 -0.08 -0.02
Purchase of Property, Plant & Equipment		 -0.04 -0.38 -0.65 -0.07 -0.09 -0.02
Sale of Property, Plant & Equipment		 - - 0.00 0.03 0.00 0.00
Net Cash From Financing Activities		 52 107 21 39 42 37
Net Cash From Continuing Financing Activities		 52 107 21 39 42 37
Issuance of Debt		 32 - 0.00 10 20 9.87
Issuance of Common Equity		 -0.52 107 0.00 7.00 23 25
Other Financing Activities, net		 0.77 -0.32 0.08 24 -0.51 1.44
Effect of Exchange Rate Changes		 -0.44 0.00 0.00 0.00 0.02 0.05

Quarterly Cash Flow Statements for Elicio Therapeutics

This table details how cash moves in and out of Elicio Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -5.17 -2.89 -1.10 -8.70 24 -8.54 0.24 3.06 -1.48 -2.05 -3.61
Net Cash From Operating Activities		 -5.19 -9.90 -12 -8.93 -7.27 -8.74 -10 -8.95 -11 -6.80 -12
Net Cash From Continuing Operating Activities		 -5.19 -9.90 -12 -8.93 -7.27 -8.74 -10 -8.95 -11 -6.80 -12
Net Income / (Loss) Continuing Operations		 -11 -8.95 -12 -7.23 -19 -14 -11 -11 -10 -7.72 -12
Consolidated Net Income / (Loss)		 -11 -8.95 -12 -7.23 -19 -14 -11 -11 -10 -7.72 -12
Depreciation Expense		 0.09 0.08 0.08 0.08 0.07 0.09 0.05 0.05 0.05 0.05 0.00
Amortization Expense		 0.19 0.21 0.21 0.21 0.24 0.27 0.26 0.23 0.23 0.42 0.31
Non-Cash Adjustments To Reconcile Net Income		 0.44 0.40 2.18 -3.27 9.49 1.22 1.13 1.68 2.89 -0.99 1.85
Changes in Operating Assets and Liabilities, net		 4.77 -1.63 -2.76 1.27 1.76 3.69 -0.35 -0.35 -4.18 1.44 -2.03
Net Cash From Investing Activities		 -0.05 - 0.00 -0.04 - -0.05 0.00 - - -0.02 0.00
Net Cash From Continuing Investing Activities		 -0.05 - 0.00 -0.04 - -0.05 0.00 - - -0.02 0.00
Net Cash From Financing Activities		 0.06 7.00 11 0.32 31 0.23 10 12 9.57 4.86 8.03
Net Cash From Continuing Financing Activities		 0.06 7.00 11 0.32 31 0.23 10 12 9.57 4.86 8.03
Issuance of Common Equity		 - 7.00 11 0.30 12 0.22 9.98 2.02 8.53 4.86 7.93
Other Financing Activities, net		 0.06 - 0.00 0.01 -0.53 0.01 0.35 0.39 1.04 0.00 0.10
Effect of Exchange Rate Changes		 0.00 - 0.00 -0.04 0.04 0.03 0.03 0.07 0.04 -0.10 0.01

Annual Balance Sheets for Elicio Therapeutics

This table presents Elicio Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 47 97 23 27 28 26
Total Current Assets		 42 91 11 16 21 19
Cash & Equivalents		 35 89 6.16 13 18 19
Prepaid Expenses		 7.69 1.69 2.92 2.73 1.90 0.75
Plant, Property, & Equipment, net		 0.16 0.45 1.15 0.72 0.48 0.30
Total Noncurrent Assets		 4.89 4.82 11 10 7.00 6.26
Other Noncurrent Operating Assets		 4.89 4.82 11 10 7.00 6.26
Total Liabilities & Shareholders' Equity		 47 97 23 27 28 26
Total Liabilities		 138 15 14 16 39 24
Total Current Liabilities		 107 11 6.87 9.76 12 8.11
Accounts Payable		 5.58 4.71 2.81 4.37 1.04 0.67
Accrued Expenses		 6.67 3.22 1.94 3.76 8.42 6.43
Other Current Liabilities		 14 1.07 0.69 0.91 0.90 1.01
Total Noncurrent Liabilities		 30 3.71 6.88 6.01 28 16
Long-Term Debt		 0.64 - - 0.00 20 9.41
Other Noncurrent Operating Liabilities		 30 3.71 6.88 6.01 7.93 6.71
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -90 82 -102 11 -11 1.64
Total Preferred & Common Equity		 -90 82 -102 11 -11 1.64
Total Common Equity		 -90 82 -102 11 -11 1.64
Common Stock		 72 297 4.86 154 183 236
Retained Earnings		 -161 -215 -107 -142 -194 -234
Treasury Stock		 -1.85 - 0.00 -0.15 -0.15 -0.15
Accumulated Other Comprehensive Income / (Loss)		 -0.33 -0.10 0.00 -0.20 -0.18 -0.13

Quarterly Balance Sheets for Elicio Therapeutics

This table presents Elicio Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 31 24 16 38 28 30 28 23
Total Current Assets		 20 14 6.69 31 21 23 21 16
Cash & Equivalents		 15 12 3.43 26 18 22 21 15
Prepaid Expenses		 3.42 1.61 2.87 3.31 1.90 0.51 0.85 1.25
Plant, Property, & Equipment, net		 0.77 0.64 0.60 0.52 0.43 0.38 0.33 0.25
Total Noncurrent Assets		 10 9.72 8.46 7.22 6.78 6.55 6.49 6.24
Other Noncurrent Operating Assets		 10 9.72 8.46 7.22 6.78 6.55 6.49 6.24
Total Liabilities & Shareholders' Equity		 31 24 16 38 28 30 28 23
Total Liabilities		 18 20 17 57 19 28 24 24
Total Current Liabilities		 11 5.95 7.59 9.02 11 9.92 6.52 7.23
Accounts Payable		 4.41 1.11 1.06 1.98 4.04 3.87 0.32 0.27
Accrued Expenses		 4.42 3.32 5.32 4.85 5.77 5.11 5.21 5.92
Other Current Liabilities		 0.96 0.88 0.85 0.88 0.93 0.95 0.98 1.04
Total Noncurrent Liabilities		 6.22 14 9.82 48 7.83 18 18 17
Long-Term Debt		 - - - 20 0.00 9.34 9.72 9.48
Other Noncurrent Operating Liabilities		 6.22 14 9.82 29 7.83 8.43 8.23 7.42
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 13 4.87 -1.65 -19 8.90 1.83 3.82 -1.44
Total Preferred & Common Equity		 13 4.87 -1.65 -19 8.90 1.83 3.82 -1.44
Total Common Equity		 13 4.87 -1.65 -19 8.90 1.83 3.82 -1.44
Common Stock		 147 159 160 161 215 218 230 244
Retained Earnings		 -133 -154 -161 -180 -205 -216 -226 -245
Treasury Stock		 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15 -0.15
Accumulated Other Comprehensive Income / (Loss)		 -0.03 -0.27 -0.24 -0.20 -0.14 -0.07 -0.03 -0.12

Annual Metrics And Ratios for Elicio Therapeutics

This table displays calculated financial ratios and metrics derived from Elicio Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 29,956,483.00 30,113,703.00 8,407,106.00 10,791,326.00 17,489,516.00
DEI Adjusted Shares Outstanding		 0.00 2,995,648.00 3,011,370.00 8,407,106.00 10,791,326.00 17,489,516.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -18.22 -9.37 -4.19 -4.81 -2.26
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 883.06% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 19.09% 53.54% -43.70% -50.16% 25.70%
EBIT Growth		 0.00% 24.74% 53.90% -42.29% -48.72% 24.91%
NOPAT Growth		 0.00% 28.89% 39.62% -50.61% -25.85% 16.17%
Net Income Growth		 0.00% 31.87% 48.31% -24.77% -47.46% 23.75%
EPS Growth		 0.00% 64.46% -4,525.39% 92.20% 38.94% 39.29%
Operating Cash Flow Growth		 0.00% -130.00% 57.87% -47.41% -13.38% 0.31%
Free Cash Flow Firm Growth		 0.00% 0.00% 62.86% 13.24% -9.12% -22.44%
Invested Capital Growth		 0.00% 84.57% 115.42% -299.64% -351.34% 25.35%
Revenue Q/Q Growth		 0.00% 900.42% -100.00% 100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 39.49% -119.30% -48.97% -10.58% 14.86%
EBIT Q/Q Growth		 0.00% 41.54% -109.90% -46.53% -10.46% 14.21%
NOPAT Q/Q Growth		 0.00% 42.02% -100.23% -51.47% -9.99% 10.94%
Net Income Q/Q Growth		 0.00% 44.50% -103.71% -36.86% -10.79% 13.71%
EPS Q/Q Growth		 0.00% 58.04% -95.72% 90.28% -122.96% 19.38%
Operating Cash Flow Q/Q Growth		 0.00% -197.59% 24.21% -8.71% 3.01% 5.01%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 39.93% -18.90% -340.24% 40.98%
Invested Capital Q/Q Growth		 0.00% 81.03% 122.66% 30.81% 61.96% -6.29%
Profitability Metrics		 - - - - - -
Gross Margin		 58.68% 98.47% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -2,182.05% -179.60% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -1,919.20% -138.84% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -2,469.86% -189.08% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -2,781.49% -192.76% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.07% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 112.54% 101.94% 114.30% 100.23% 99.38% 100.91%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 88.57% 1,220.60% -62.39% -346.95% -170,157.38% 817.92%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -2,234.36% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -150.24% -74.42% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -169.19% -75.87% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 88.57% 1,220.60% 14.24% 1,552.14% -200,841.49% 817.92%
Return on Equity Simple (ROE_SIMPLE)		 88.57% -66.96% 27.62% -309.46% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -39 -28 -17 -25 -31 -26
NOPAT Margin		 -1,343.44% -97.18% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 95.30% -119.47% -24.02% -95.07% -330.04% -332.69%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -220.01% -361.04% -239.06%
Cost of Revenue to Revenue		 41.32% 1.53% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 624.51% 65.30% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 1,353.37% 172.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 1,979.90% 237.31% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -71 -54 -25 -35 -52 -39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -63 -51 -24 -34 -51 -38
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 1.07 0.00 6.16 0.00 85.10
Price to Tangible Book Value (P/TBV)		 0.00 1.07 0.00 6.16 0.00 85.10
Price to Revenue (P/Rev)		 27.78 3.07 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 114.22 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 33.84 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 -0.58 0.00 0.00 0.00 -1.77 5.75
Long-Term Debt to Equity		 -0.01 0.00 0.00 0.00 -1.77 5.75
Financial Leverage		 -0.48 5.07 -1.07 -1.05 -202.74 0.82
Leverage Ratio		 -0.52 -16.09 1.32 2.46 906.95 -5.59
Compound Leverage Factor		 -0.59 -16.40 1.51 2.46 901.31 -5.64
Debt to Total Capital		 -135.64% 0.00% 0.00% 0.00% 229.70% 85.19%
Short-Term Debt to Total Capital		 -133.99% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 -1.65% 0.00% 0.00% 0.00% 229.70% 85.19%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 1,245.77% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 235.64% 100.00% -1,145.77% 100.10% -129.70% 14.81%
Debt to EBITDA		 -0.83 0.00 0.00 0.00 -0.39 -0.25
Net Debt to EBITDA		 -0.28 0.00 0.00 0.00 -0.02 0.24
Long-Term Debt to EBITDA		 -0.01 0.00 0.00 0.00 -0.39 -0.25
Debt to NOPAT		 -1.35 0.00 0.00 0.00 -0.64 -0.36
Net Debt to NOPAT		 -0.45 0.00 0.00 0.00 -0.04 0.35
Long-Term Debt to NOPAT		 -0.02 0.00 0.00 0.00 -0.64 -0.36
Altman Z-Score		 -10.95 -0.19 -8.93 -8.64 -14.53 -13.69
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 122.82% 547.36% -18.03% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.39 8.08 1.56 1.68 1.80 2.38
Quick Ratio		 0.32 7.86 0.90 1.32 1.53 2.29
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -67 -25 -22 -24 -29
Operating Cash Flow to CapEx		 -55,824.39% -13,780.89% -3,391.28% -102,168.75% -44,128.57% -230,950.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -71.40 -6.95 -47.73 -51.97 -25.56
Operating Cash Flow to Interest Expense		 -2.59 -55.88 -6.17 -72.01 -81.47 -32.61
Operating Cash Flow Less CapEx to Interest Expense		 -2.59 -56.29 -6.35 -72.08 -81.65 -32.63
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.06 0.39 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 18.46 93.29 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.21 0.08 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 1,710.90 4,336.17 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -1,710.90 -4,336.17 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -47 -7.25 1.12 -2.23 -10 -7.52
Invested Capital Turnover		 -0.06 -1.04 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 40 8.37 -3.35 -7.84 2.55
Enterprise Value (EV)		 97 -1.88 128 56 56 130
Market Capitalization		 80 87 24 70 55 139
Book Value per Share		 ($6.13) $2.72 ($3.39) $1.35 ($1.05) $0.09
Tangible Book Value per Share		 ($6.13) $2.72 ($3.39) $1.35 ($1.05) $0.09
Total Capital		 -38 82 8.92 11 8.72 11
Total Debt		 52 0.00 0.00 0.00 20 9.41
Total Long-Term Debt		 0.64 0.00 0.00 0.00 20 9.41
Net Debt		 17 -89 -7.80 -14 1.24 -9.16
Capital Expenditures (CapEx)		 0.04 0.38 0.65 0.03 0.08 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -48 -8.81 -3.95 -7.02 -9.63 -7.36
Debt-free Net Working Capital (DFNWC)		 -14 80 3.85 6.59 9.17 11
Net Working Capital (NWC)		 -65 80 3.85 6.59 9.17 11
Net Nonoperating Expense (NNE)		 41 27 12 10 20 13
Net Nonoperating Obligations (NNO)		 43 -89 -7.80 -14 1.24 -9.16
Total Depreciation and Amortization (D&A)		 8.29 2.69 1.06 1.17 1.25 1.35
Debt-free, Cash-free Net Working Capital to Revenue		 -1,678.09% -31.10% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 -476.46% 282.39% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 -2,262.22% 282.39% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($19.30) ($12.90) ($6.96) ($4.25) ($2.58)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 2.82M 3.00M 5.06M 12.20M 15.31M
Adjusted Diluted Earnings per Share		 $0.00 ($19.30) ($12.90) ($6.96) ($4.25) ($2.58)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 2.82M 3.00M 5.06M 12.20M 15.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 3.00M 3.01M 10.24M 15.95M 18.40M
Normalized Net Operating Profit after Tax (NOPAT)		 -39 -28 -17 -25 -31 -26
Normalized NOPAT Margin		 -1,342.03% -97.18% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -2,779.48% -192.76% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -8.04 -56.83 -6.86 -77.34 -114.78 -34.61
NOPAT to Interest Expense		 -4.37 -29.21 -4.62 -55.11 -69.21 -23.30
EBIT Less CapEx to Interest Expense		 -8.05 -57.23 -7.05 -77.41 -114.96 -34.62
NOPAT Less CapEx to Interest Expense		 -4.38 -29.61 -4.80 -55.18 -69.39 -23.31
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% -6.72% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -7.14% 0.00% 0.00%

Quarterly Metrics And Ratios for Elicio Therapeutics

This table displays calculated financial ratios and metrics derived from Elicio Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 8,388,457.00 8,407,106.00 10,235,469.00 10,270,285.00 10,774,574.00 10,791,326.00 15,953,524.00 15,996,976.00 16,338,284.00 17,489,516.00 18,396,074.00
DEI Adjusted Shares Outstanding		 8,388,457.00 8,407,106.00 10,235,469.00 10,270,285.00 10,774,574.00 10,791,326.00 15,953,524.00 15,996,976.00 16,338,284.00 17,489,516.00 18,396,074.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.27 -1.06 -1.16 -0.70 -1.75 -1.30 -0.70 -0.66 -0.62 -0.44 -0.64
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -80.35% -482.40% -53.60% -0.53% -76.44% -55.14% 6.21% -45.99% 48.45% 48.17% -3.04%
EBIT Growth		 -76.15% -552.25% -55.18% 2.28% -74.90% -54.16% 5.87% -43.98% 47.81% 46.15% -2.94%
NOPAT Growth		 -86.67% -338.72% -31.21% -40.47% 3.96% -43.49% -4.83% 7.63% 22.23% 34.39% 1.25%
Net Income Growth		 -48.07% -1,791.68% -47.30% 4.37% -76.75% -56.49% 5.23% -46.09% 46.48% 44.89% -5.48%
EPS Growth		 94.40% 150.54% 95.36% 75.48% -9.45% -104.93% 24.35% -3.13% 56.83% 57.94% 25.29%
Operating Cash Flow Growth		 3.73% -36.00% -48.94% 5.77% -40.29% 11.63% 16.52% -0.25% -52.41% 22.27% -15.08%
Free Cash Flow Firm Growth		 75.23% 42.55% 150.33% 97.25% 273.23% 50.63% -146.07% -442.07% -256.33% -449.24% -111.42%
Invested Capital Growth		 34.60% -299.64% -173.21% -391.89% -720.99% -351.34% -32.45% -99.47% 73.29% 25.35% 31.79%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -50.64% 15.96% -31.76% 39.73% -164.38% 26.11% 20.35% 6.18% 6.64% 25.71% -58.35%
EBIT Q/Q Growth		 -44.20% 15.44% -30.81% 38.74% -158.11% 25.47% 20.13% 6.30% 6.45% 23.09% -52.68%
NOPAT Q/Q Growth		 -38.50% 12.80% -9.04% -6.67% 5.31% -30.29% 20.34% 6.01% 20.28% -9.91% -19.91%
Net Income Q/Q Growth		 -41.00% 16.03% -32.16% 38.88% -160.59% 25.66% 19.96% 5.78% 4.53% 23.46% -53.19%
EPS Q/Q Growth		 51.34% 1,807.87% -105.30% 44.35% -117.19% 23.02% 18.69% 24.14% 9.09% 25.00% -44.44%
Operating Cash Flow Q/Q Growth		 45.28% -90.84% -22.51% 26.35% 18.53% -20.21% -15.73% 11.55% -23.87% 38.69% -71.33%
Free Cash Flow Firm Q/Q Growth		 14.78% 65.13% 438.86% -102.73% 5,460.84% -109.94% -216.18% 67.82% -1,446.06% 65.08% -21.71%
Invested Capital Q/Q Growth		 -272.05% 30.81% -242.65% 28.44% -383.92% 61.96% -0.56% -7.77% 35.19% -6.29% 8.11%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 101.00% 98.84% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.73% 99.16% 99.02% 98.80% 99.75% 99.49% 99.70% 100.25% 102.30% 101.82% 102.16%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -81.00% -346.95% -175.11% -353.01% 1,643.61% -170,157.38% -744.59% -60,013.19% 604.57% 817.92% -1,076.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -81.00% 1,552.14% -175.11% -353.01% 1,643.61% -200,841.49% -744.59% -60,013.19% 604.57% 817.92% -1,076.34%
Return on Equity Simple (ROE_SIMPLE)		 -193.56% 0.00% -800.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.54 -6.57 -7.17 -7.65 -7.24 -9.43 -7.52 -7.06 -5.63 -6.19 -7.42
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.70% -22.19% -22.32% 3.28% -96.60% -73.91% -23.41% -42.21% -48.41% -38.61% -35.92%
Return On Investment Capital (ROIC_SIMPLE)		 - -57.81% -147.20% 462.88% -852.86% -108.16% -84.40% -63.23% -41.60% -56.05% -92.33%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -11 -9.13 -12 -7.32 -19 -14 -11 -11 -9.86 -7.58 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -8.85 -12 -7.02 -19 -14 -11 -10 -9.57 -7.11 -11
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.34 6.16 15.97 0.00 0.00 0.00 11.04 67.34 46.84 85.10 0.00
Price to Tangible Book Value (P/TBV)		 5.34 6.16 15.97 0.00 0.00 0.00 11.04 67.34 46.84 85.10 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 -1.04 -1.77 0.00 5.09 2.55 5.75 -6.59
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 -1.04 -1.77 0.00 5.09 2.55 5.75 -6.59
Financial Leverage		 -1.13 -1.05 -0.94 -1.16 4.21 -202.74 -2.29 -91.05 1.21 0.82 -3.28
Leverage Ratio		 1.45 2.46 1.49 2.44 -12.17 906.95 3.82 248.78 -4.40 -5.59 6.81
Compound Leverage Factor		 1.42 2.43 1.47 2.41 -12.14 902.31 3.81 249.39 -4.50 -5.69 6.95
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 2,336.28% 229.70% 0.00% 83.58% 71.81% 85.19% 117.88%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 2,336.28% 229.70% 0.00% 83.58% 71.81% 85.19% 117.88%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.10% 100.00% 100.00% -2,236.28% -129.70% 100.00% 16.42% 28.19% 14.81% -17.88%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.43 -0.39 0.00 -0.17 -0.22 -0.25 -0.25
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.16 -0.02 0.00 0.24 0.24 0.24 0.14
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.43 -0.39 0.00 -0.17 -0.22 -0.25 -0.25
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.69 -0.64 0.00 -0.30 -0.33 -0.36 -0.36
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.26 -0.04 0.00 0.41 0.37 0.35 0.21
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.69 -0.64 0.00 -0.30 -0.33 -0.36 -0.36
Altman Z-Score		 -4.49 -5.49 -7.64 -14.48 -6.95 -10.07 -8.06 -8.22 -7.32 -9.65 -11.47
Noncontrolling Interest Sharing Ratio		 0.00% 547.36% 0.00% 0.00% 0.00% -18.03% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.74 1.68 2.37 0.88 3.40 1.80 1.83 2.28 3.29 2.38 2.24
Quick Ratio		 1.29 1.32 1.99 0.45 2.88 1.53 1.61 2.23 3.16 2.29 2.07
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -9.25 -3.22 11 -0.30 16 -1.59 -5.03 -1.62 -25 -8.74 -11
Operating Cash Flow to CapEx		 -11,522.22% 0.00% 0.00% 0.00% 0.00% -19,431.11% 0.00% 0.00% 0.00% -42,481.25% 0.00%
Free Cash Flow to Firm to Interest Expense		 -9,246.70 -3,224.40 303.51 -6.10 116.92 -6.83 -28.60 -8.35 -58.78 -25.94 -26.15
Operating Cash Flow to Interest Expense		 -5,185.00 -9,895.00 -336.72 -182.20 -53.09 -37.53 -57.49 -46.13 -26.02 -20.17 -28.61
Operating Cash Flow Less CapEx to Interest Expense		 -5,230.00 -9,895.00 -336.64 -182.20 -53.09 -37.72 -57.49 -46.13 -26.02 -20.22 -28.61
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.23 -2.23 -7.65 -5.47 -26 -10 -10 -11 -7.08 -7.52 -6.91
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.71 -3.35 -18 -7.35 -23 -7.84 -2.48 -5.44 19 2.55 3.22
Enterprise Value (EV)		 54 56 65 38 47 56 79 111 168 130 191
Market Capitalization		 71 70 78 42 54 55 98 123 179 139 197
Book Value per Share		 $1.58 $1.35 $0.48 ($0.16) ($1.76) ($1.05) $0.83 $0.11 $0.23 $0.09 ($0.08)
Tangible Book Value per Share		 $1.58 $1.35 $0.48 ($0.16) ($1.76) ($1.05) $0.83 $0.11 $0.23 $0.09 ($0.08)
Total Capital		 13 11 4.87 -1.65 0.85 8.72 8.90 11 14 11 8.04
Total Debt		 0.00 0.00 0.00 0.00 20 20 0.00 9.34 9.72 9.41 9.48
Total Long-Term Debt		 0.00 0.00 0.00 0.00 20 20 0.00 9.34 9.72 9.41 9.48
Net Debt		 -17 -14 -13 -3.82 -7.50 1.24 -19 -13 -11 -9.16 -5.47
Capital Expenditures (CapEx)		 0.05 0.00 -0.00 0.00 0.00 0.05 0.00 0.00 0.00 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.07 -7.02 -4.34 -4.72 -5.71 -9.63 -9.51 -9.41 -5.66 -7.36 -5.98
Debt-free Net Working Capital (DFNWC)		 8.45 6.59 8.18 -0.90 22 9.17 9.52 13 15 11 8.97
Net Working Capital (NWC)		 8.45 6.59 8.18 -0.90 22 9.17 9.52 13 15 11 8.97
Net Nonoperating Expense (NNE)		 3.12 2.37 4.66 -0.42 12 4.57 3.69 3.50 4.45 1.53 4.40
Net Nonoperating Obligations (NNO)		 -17 -14 -13 -3.82 -7.50 1.24 -19 -13 -11 -9.16 -5.47
Total Depreciation and Amortization (D&A)		 0.27 0.29 0.29 0.29 0.32 0.35 0.31 0.28 0.28 0.47 0.31
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.27) $21.69 ($1.15) ($0.64) ($1.39) ($1.07) ($0.87) ($0.66) ($0.60) ($0.45) ($0.65)
Adjusted Weighted Average Basic Shares Outstanding		 8.38M 5.06M 10.27M 11.28M 13.58M 12.20M 12.95M 16.06M 16.69M 15.31M 18.21M
Adjusted Diluted Earnings per Share		 ($1.27) $21.69 ($1.15) ($0.64) ($1.39) ($1.07) ($0.87) ($0.66) ($0.60) ($0.45) ($0.65)
Adjusted Weighted Average Diluted Shares Outstanding		 8.38M 5.06M 10.27M 11.28M 13.58M 12.20M 12.95M 16.06M 16.69M 15.31M 18.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.41M 10.24M 10.27M 10.77M 10.79M 15.95M 16.00M 16.34M 17.49M 18.40M 19.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.54 -6.57 -7.17 -7.65 -7.24 -9.43 -7.52 -7.06 -5.63 -6.19 -7.42
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -10,798.00 -9,131.00 -331.78 -149.33 -137.85 -60.41 -63.88 -54.30 -23.14 -22.49 -28.43
NOPAT to Interest Expense		 -7,539.70 -6,574.40 -199.13 -156.06 -52.85 -40.49 -42.70 -36.41 -13.22 -18.37 -18.23
EBIT Less CapEx to Interest Expense		 -10,843.00 -9,131.00 -331.69 -149.33 -137.85 -60.61 -63.88 -54.30 -23.14 -22.54 -28.43
NOPAT Less CapEx to Interest Expense		 -7,584.70 -6,574.40 -199.05 -156.06 -52.85 -40.68 -42.70 -36.41 -13.22 -18.41 -18.23
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -9.20% -6.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -9.78% -7.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Elicio Therapeutics (NASDAQ: ELTX) remains a pre-revenue biotechnology company with no product sales, persistent operating losses, and a business model that depends heavily on external financing. The latest Q1 2026 results show a continued cash burn, but the company still ended the quarter with a meaningful cash balance and no new investing outflows.

  • Q1 2026 ended with $15.0 million in cash and equivalents, giving the company some near-term liquidity despite ongoing losses.
  • The company reported no cash used in investing activities in Q1 2026, suggesting a relatively light capital spending period.
  • Elicio raised $7.9 million through common equity issuance in Q1 2026, helping offset operating losses.
  • Research and development spending in Q1 2026 was $6.8 million, down from $10.7 million in Q4 2024, which may indicate more controlled development spending versus prior peaks.
  • Operating expenses in Q1 2026 were $10.6 million, lower than several earlier quarters in 2024, showing some moderation in the burn rate.
  • Revenue remained $0 in every period provided, so the business is still entirely dependent on financing rather than commercial sales.
  • Q1 2026 basic and diluted EPS were both $(0.65), reflecting continued losses on a per-share basis.
  • The company carries $9.5 million of long-term debt as of Q1 2026, which is not excessive but does add balance-sheet leverage for a cash-burning biotech.
  • Total liabilities of $24.1 million exceeded total equity of $(1.4) million in Q1 2026, meaning the balance sheet remains under pressure.
  • Shares outstanding have increased materially over time, with Q1 2026 weighted average basic shares at 18.2 million versus 10.3 million in Q1 2024, indicating meaningful dilution.
  • Elicio posted a Q1 2026 net loss of $11.8 million and negative operating cash flow of $11.6 million, underscoring ongoing cash burn.
  • Cash declined from $20.6 million in Q3 2025 to $15.0 million in Q1 2026, showing that liquidity is being consumed quickly.
  • The company has recorded negative equity in several periods, including $(1.4) million in Q1 2026 and $(18.9) million in Q3 2024, highlighting a stretched capital structure historically.
  • Operating losses have remained large for years, with quarterly net losses generally ranging from about $7 million to $19 million across the periods provided.
  • Funding needs have repeatedly been met through share issuance and debt raises, which can be dilutive and may pressure existing shareholders over time.

Bottom line: ELTX is still in a classic development-stage biotech profile: no revenue, recurring losses, and ongoing reliance on capital markets. The good news is that the company still has cash on hand and raised additional equity in the latest quarter. The concern is that cash burn remains substantial, so future dilution or additional financing appears likely unless clinical progress changes the story.

07/23/26 12:16 AM ETAI Generated. May Contain Errors.

Elicio Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Elicio Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Elicio Therapeutics' net income appears to be on a downward trend, with a most recent value of -$39.57 million in 2025, falling from -$80.11 million in 2020. The previous period was -$51.90 million in 2024. Check out Elicio Therapeutics' forecast to explore projected trends and price targets.

Elicio Therapeutics' total operating income in 2025 was -$37.71 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $37.71 million

Over the last 5 years, Elicio Therapeutics' total revenue changed from $2.88 million in 2020 to $0.00 in 2025, a change of -100.0%.

Elicio Therapeutics' total liabilities were at $24.23 million at the end of 2025, a 38.7% decrease from 2024, and a 82.4% decrease since 2020.

In the past 5 years, Elicio Therapeutics' cash and equivalents has ranged from $6.16 million in 2022 to $88.76 million in 2021, and is currently $18.56 million as of their latest financial filing in 2025.

Over the last 5 years, Elicio Therapeutics' book value per share changed from -6.13 in 2020 to 0.09 in 2025, a change of -101.5%.


Related Companies

Financial statements for NASDAQ:ELTX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel